NHS patients with an aggressive form of blood cancer are to benefit from a life-extending daily tablet after the health service became Europe’s first to routinely commission the treatment. The new targeted treatment, quizartinib, can now be prescribed to newly-diagnosed patients with a specific type of leukaemia, boosting their chance of remission and long-term survival. […]
Read More on the NHS website.